ECM
IONS icon

Everence Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Everence Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$494K Hold
6,232
– – 0.03% 421
2026
Q1 		$468K Sell
6,232
-538
-8% -$42.5K 0.03% 398
2025
Q4 		$536K Hold
6,770
– – 0.03% 372
2025
Q3 		$443K Hold
6,770
– – 0.03% 433
2025
Q2 		$267K Hold
6,770
– – 0.02% 628
2025
Q1 		$204K Hold
6,770
– – 0.01% 737
2024
Q4 		$237K Buy
+6,770
New +$253K 0.02% 696

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Everence Capital Management's IONS Position: Q2 2026 in Review

Everence Capital Management held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 6,232 shares worth $494K. The position accounts for 0.03% of the portfolio, ranked #421.

Everence Capital Management first reported a position in IONS in Q4 2024 and has held it in 7 quarters since. The position peaked at $536K in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Everence Capital Management held 6,232 shares of Ionis Pharmaceuticals worth $494K as of Q2 2026.
  • Everence Capital Management left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up 0.03% of Everence Capital Management's portfolio in Q2 2026, its #421 holding.
  • Everence Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Everence Capital Management's Ionis Pharmaceuticals position peaked at $536K in Q4 2025.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.